Third consecutive profitable quarter with continued strong growth
|
|
- Doris Lucas
- 5 years ago
- Views:
Transcription
1 Interim report for the period 1 January 30 September 2015 Announcement No. 10/2015 To NASDAQ Copenhagen Exiqon A/S Skelstedet Vedbæk Denmark 26 October 2015 Phone: Fax: exiqon@exiqon.com Third consecutive profitable quarter with continued strong growth Exiqon A/S (NASDAQ OMX Copenhagen: EXQ ) today announced results for the third quarter and first nine months of 2015: Q3 YTD Q3 YTD Q3 YTD Financial Highlights (DKK million) Q Q Q3 change change Revenue % % Gross profit % % EBITDA % % EBIT % N/A Net profit % % Cash flows from operating activities N/A N/A Summarized financial numbers are compared to full year outlook on p.3. Revenue highlights Exiqon successfully continues to execute its growth strategy towards becoming the leading provider of flexible solutions for RNA analysis by leveraging existing capabilities and capture new markets. RNA services and product sales (excluding OEM) are the key drivers for Exiqon s growth. In the third quarter products and services sales increased 17% to DKK 30.7 million (DKK 26.3 million): o Products sales offer high potential for growth as Exiqon increasingly targets new sizable markets for RNA sequencing and RNA functional analysis. At the end of the second quarter, Exiqon launched a new advanced qpcr product portfolio, ExiLERATE, for real-time PCR detection of mrna and lncrna as part of the XploreRNA initiative. In the third quarter, product sales increased 29% to DKK 24.7 million (DKK 19.1 million). o Services pave the way for the development of new proprietary products. The Company s current capacity for RNA sequencing services is already fully booked until year-end. In the third quarter, however, sales decreased 17% to DKK 5.9 million (DKK 7.1 million) due to a seasonal short fall in qpcr services. Other income include license income and grant funding of Exiqon s development of novel diagnostics within prostate and colorectal cancers that hold promise of transforming current healthcare practices and improve patient care. In the third quarter other income decreased 12% to DKK 4.5 million (DKK 5.1 million). Operational highlights Exiqon today provides an update on the diagnostic programs that were recently exclusively licensed from Aarhus University Hospital, Department of Molecular Medicine (MOMA); The sales channel will be commercially marketed beginning next month following a significant update and new functionality. In a comment CEO Lars Kongsbak said: I am extremely pleased with the 29% strong growth in our product sales this quarter following recent product launches. We are also excited about beginning marketing of the platform next month, which will help position our products for validation of NGS data. Feedback from our first customers has been overwhelmingly positive and we have high expectations to this innovative new sales channel targeting RNA sequencing customers. Exiqon maintains its full year guidance of revenues of DKK million and EBITDA around DKK 10 million based on an average USD/DKK exchange rate of DKK 6.50.
2 KEY FIGURES AND RATIOS EXIQON GROUP (UNAUDITED) (DKK 000 except key figures and ratios) Basic and diluted EPS have been calculated in accordance with IAS 33 Earnings per share. Other ratios have been calculated in accordance with Recommendations & Financial Ratios 2015 issued by the Danish Society of Financial Analysts, dated April (*) EBITDA (defined as Earnings Before Special Items, Interest, Tax, Depreciation and Amortization) includes non-cash costs of share-based payment of tdkk 829 in the first nine months of Income statement Revenue 38,364 34, ,402 98, ,392 Production costs -14,920-14,009-41,190-34,939-47,193 Gross profit 23,444 20,816 74,212 63,079 85,199 Research and development costs -7,459-5,977-23,511-19,115-26,283 Sales and marketing costs -10,736-9,991-34,867-30,892-43,087 Administrative costs -3,940-4,025-12,754-13,305-18,911 EBITDA *) 3,131 2,522 8,366 4,230 3,107 Operating profit/(loss) (EBIT) 1, , ,082 Profit/(loss) for the period 618 1, ,780 Total Comprehensive profit/(loss) for the period 727 1,742 1,263 1,338-2,058 Balance sheet Assets Intangible assets 61,025 60,836 60,433 Property, plant and equipment 11,701 12,684 12,023 Non-current assets 75,468 76,812 75,211 Cash and cash equivalents 25,411 21,955 20,084 Current assets 66,619 60,786 62,451 Total assets 142, , ,662 Equity and liabilities Equity 80,107 80,436 78,015 Non-current liabilities 2,791 18,736 18,155 Current liabilities 59,189 38,426 41,492 Total liabilities 61,980 57,162 59,647 Total equity and liabilities 142, , ,662 Cash flow statement Depreciation, amortization and impairment 5,286 4,468 6,197 Cash flows from operating activities 10, ,434 Cash flows from investing activities -3,818-4,322-4,831 Cash flows from financing activities -2,047-2,669-2,859 Cash and cash equivalents at the end of period 25,411 21,955 20,084 Key figures and ratios Number of shares, average 36,874,082 36,874,082 36,874,082 Basic EPS (DKK) Diluted EPS (DKK) Gross margin 61.1% 59.8% 64.3% 64.4% 64.4% Assets/Equity (gearing) Average number of employees Market price per share (DKK) Market capitalisation (DKK million) Price / net asset value Net interest bearing debt / Equity Net interest bearing debt / EBITDA Interest coverage Page 2 of 9
3 MANAGEMENT REPORT Reported figures are for the full reporting period unless otherwise stated. Figures for the comparable reporting period in the previous year are stated in parenthesis. In the first nine months of 2015 the average USD/DKK exchange rate applied to translate revenue and expenses was DKK 6.71 (DKK 5.53). Revenue In the first nine months of 2015 total revenue increased 18% to DKK million (DKK 98.0 million). Services and product sales (excluding OEM) drive growth. Sales increased 21% to DKK 92.4 million (DKK 76.0 million) excluding OEM sales of DKK 8.8 million (DKK 7.8 million) in the first nine months of In Europe services and product sales (excluding OEM) increased 8% to DKK 41.2 million (DKK 38.1 million), and in North America sales increased 40% to DKK 39.0 million (DKK 27.8 million) benefitting from an improved pricing situation following recent increase in the USD/DKK exchange rate. Rest of World sales increased 21% to DKK 12.2 million (DKK 10.1 million). Services sales initially drive growth as the company targets new markets for RNA sequencing and RNA functional analysis. In the first nine months of 2015 services sales increased 25% to DKK 18.4 million (DKK 14.7 million) and product sales (excluding OEM) increased 21% to DKK 74.0 million (DKK 61.3 million). License income accounted for DKK 6.6 million (DKK 7.3 million) and contract research income, reflective of third party funding of Exiqon s development of novel diagnostics, totaled DKK 5.4 million (DKK 5.1 million). Gross profit and margins In the first nine months of 2015 gross profit increased 18% to DKK 74.2 million (DKK 63.1 million) as a result of higher sales volumes. In the same period gross margins on product sales and services excluding other income increased marginally to 60.2% (59.2%). Improved economies of scale and automated solutions will allow for continued improvement of margins over time as the company continues to execute its growth strategy. In the third quarter of 2015 gross profit increased 13% to DKK 23.4 million (DKK 20.8 million) and gross margins on product sales and services excluding other income improved to 55.9% (52.9%). Operating costs In the first nine months of 2015 operating costs excluding production costs increased 12% to DKK 71.1 million (DKK 63.3 million) in line with the company s strategy to maximize investment in R&D and S&M without compromising EBITDA profitability. In the third quarter of 2015 operating costs excluding production costs increased 11% to DKK 22.1 million (DKK 20.0 million). EBITDA and EBIT EBITDA improved to DKK 8.4 million (DKK 4.2 million) whereas EBIT was affected by higher depreciations following increased investments and improved to DKK 3.1 million (DKK -0.2 million). In the third quarter of 2015 EBITDA improved to DKK 3.1 million (DKK 2.5 million) and EBIT to DKK 1.3 million (DKK 0.8 million). Tax Net results for the first nine months of 2015 have been positive. The company continues to monitor whether to capitalize part of Exiqon A/S tax-asset in Summarized financial numbers compared to full year outlook In the table below, the company's realized performance for the first nine months of 2015 is summarized and compared to the outlook for the full year; including an adjustment of the realized numbers to the exchange rate used as basis for the full year outlook (USD/DKK 6.50): (DKK million) Realized 2015 (USD/DKK 6.71) Realized 2015 adjusted to USD/DKK 6.50 Outlook 2015 (USD/DKK 6.50) Revenue EBITDA ~10 Cash flows Cash flows from operating activities were DKK 10.7 million (DKK -1.0 million) primarily reflective of cash flows from primary activities of DKK 13.4 million (DKK -1.9 million) whereas net interest and value gains amounted to DKK -2.7 million (DKK 0.9 million). Page 3 of 9
4 Equity and capital resources Equity amounted to DKK 80.1 million (DKK 80.4 million). Trade receivables increased to DKK 19.8 million (DKK 18.3 million) and trade payables increased to DKK 11.5 million (DKK 10.8 million) as a result of continued cash management efforts. On 30 September 2015 cash and cash equivalents totalled DKK 25.4 (DKK 22.0 million) including DKK 10 million in credit that is subject to repayment by 10 January 2016 and proceeds of DKK 15 million from the company's corporate bond that is subject to repayment by 1 March Management expects that the company s future capital needs are covered by existing arrangements. Any requirement for additional capital in the future, we will seek to cover by new arrangements, or by increasing the current share capital under existing authorizations to the Supervisory Board. UPDATE ON DIAGNOSTICS Today Exiqon provides an update on the diagnostic programs for which the Company exclusively licensed two sets of validated prostate cancer mirna biomarkers from Aarhus University Hospital, Department of Molecular Medicine (MOMA) on 2 September Prostate cancer constitutes ~14% of all diagnosed cancers with about incidences in Europe annually. Non-invasive diagnosis of prostate cancer based on urine samples (early detection): One biomarker profile relates to non-invasive diagnosis of prostate cancer based on urine samples. The objective of Exiqon s program for early detection is to correctly diagnose individuals with intermediate levels of Prostate Specific Antigen (PSA) in the blood. Today, a PSA test is the most widely used diagnostic and screening tool for prostate cancer, however, it is not specific for prostate cancer, and may lead to unnecessary biopsy testing. Up to 70% of PSA positive tests turn out to be false positives. Besides, not all prostate cancer cases result in elevated PSA levels, and up to 15 % of PSA negative cancers may today go by undetected. In a collaboration with MOMA, Exiqon has applied its sensitive LNA based qpcr technology to identify mirna biomarkers in urine samples which allow for highly accurate diagnosis of individuals with intermediate levels of PSA. These mirna biomarkers have now been validated in independent cohorts. As a result, Exiqon has acquired all commercial rights. A final retrospective validation study is currently ongoing and scheduled to be completed by summer 2016 upon which results will be published. Provided results are in line with previous validation studies, this diagnostic test will be positioned for commercial partnering next year. Patient stratification for improved treatment selection based on tissue samples: The other biomarker profile relates to patient stratification for improved treatment selection based on tissue samples collected as fine needle biopsies. Exiqon conducts two parallel programs together with MOMA. The objective of Exiqon s programs is to significantly improve the clinical management of prostate cancer patients. Fine needle biopsies are difficult to interpret and analyse. This may lead to undetected and misdiagnosed cases. Particular challenging, however, is the differentiation between indolent (nonaggressive) tumours from aggressive prostate cancer that requires treatment. In consequence, indolent (non-aggressive) tumours may be over-treated with serious consequences for the patients and considerable costs to the health care systems. One treatment selection program is based on the analysis of methylation of DNA. The methylation biomarkers have been retrospectively validated in independent cohorts and the results are published. Exiqon acquired all commercial rights in November To further increase sensitivity and specificity of a test, Exiqon is in the process of converting the current detection assays to Exiqons LNA based qpcr technology. Once the assays have been migrated, clinical cross-validation studies will be conducted on relevant cohorts. The other treatment selection program is based on mirna biomarkers which originally were identified and since validated in two independent cohorts using Exiqon s LNA based qpcr technology. A scientific publication of the results is under preparation. As was announced on 2 September of 2015 Exiqon has acquired all commercial rights. These biomarkers may prove an alternative to the above mentioned test, or further strengthen such test by use of complementary biomarkers. The potential synergistic value of the methylation and the mirna based tests will be concluded in H Prospective validation of this prognostic test may be required before commercial partnering and necessary third party funding will be required to conduct such a study. Page 4 of 9
5 FINANCIAL OUTLOOK 2015 Exiqon expects revenues between DKK million and EBITDA around DKK 10 million in The outlook for 2015 is based on an average USD/DKK exchange rate of DKK In addition to exchange rates, the outlook depends primarily on organic growth in Exiqon s services and product sales, excluding OEM sales to licensees. Exiqon continues to pursue license and commercial partnering opportunities during No significant one-time costs are included in the outlook for 2015, nor are any expected. Any costs related to new warrant grants are not included in the guidance for STATEMENT BY THE EXECUTIVE BOARD AND SUPERVISORY BOARD ON THE INTERIM REPORT The Supervisory Board and the Executive Board have today considered and approved the interim report of Exiqon A/S for the period 1 January 30 September The interim report has been prepared in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim report is unaudited. We consider the accounting policies to be appropriate, the accounting estimates made to be reasonable and the overall presentation of the interim report to be adequate, so that the interim report, in our opinion, gives a true and fair view of the assets, liabilities, financial position and results of operations and cash flows of the group for the period 1 January 30 September We consider the Management s report to give a true and fair description of the development in the Group s activities and economic situation, the results of operations and the Group s financial position as a whole and a description of the significant risks and uncertainty factors, which the Group faces. Vedbaek, 26 October 2015 Executive Board Lars Kongsbak, CEO Hans Henrik Chrois Christensen, CFO Supervisory Board Erik Walldén, chairman Thorleif Krarup, deputy chairman Michael Nobel Per Wold-Olsen Rodney Turner Additional information Lars Kongsbak, CEO, phone (cell: ) Hans Henrik Chrois Christensen, CFO, phone (cell: ) Forward-looking statements Certain parts of this release contain forward-looking information with respect to the plans, projections and future performance of the company, each of which involves significant uncertainties. The company s actual results may differ materially from the information set forth in these statements. Timelines relating to collaborative diagnostic programs should be considered approximate. Page 5 of 9
6 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED) Note Revenue 2,3 38,364 34, ,402 98, ,392 Production costs -14,920-14,009-41,190-34,939-47,193 Gross profit 23,444 20,816 74,212 63,079 85,199 Research and development costs -7,459-5,977-23,511-19,115-26,283 Sales and marketing costs -10,736-9,991-34,867-30,892-43,087 Administrative costs -3,940-4,025-12,754-13,305-18,911 Operating profit/(loss) (EBIT) 1, , ,082 Financial income 710 1,031 4,292 1,683 2,210 Financial expenses -1,512-1,398-7,235-3,234-5,111 Profit/(loss) before tax ,784-5,983 Tax on profit/(loss) for the period ,646 3,203 Profit/(loss) for the period 618 1, ,780 Other comprehensive income Items that may be reclassified subsequently to profit or loss: Exchange adjustments relating to foreign subsidiaries Total comprehensive income for the period 727 1,742 1,263 1,338-2,058 Earnings per share Earnings per share Diluted earnings per share Page 6 of 9
7 CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED) Note 30 Sep Sep Dec Goodwill 49,368 49,368 49,368 Acquired patent rights 4,198 5,149 4,887 Acquired software licenses 6,118 6,015 5,932 Intangible assets under construction 1, Intangible assets 61,025 60,836 60,433 Leasehold improvements Production and laboratory equipment 7,671 10,043 9,474 Fixtures and fittings, tools and equipment 3,253 1,884 1,777 Tangible assets under construction Property, plant and equipment 11,701 12,684 12,023 Deferred tax assets 1,383 1,563 1,430 Deposits 1,359 1,729 1,325 Financial assets 2,742 3,292 2,755 Non-current assets 75,468 76,812 75,211 Inventories 12,482 13,463 13,963 Trade receivables 19,762 18,335 22,147 Other receivables 2,829 1,589 1,200 Refund from Tax Authorities 4,321 4,250 3,690 Prepayments 1,814 1,194 1,367 Receivables 28,726 25,368 28,404 Cash and cash equivalents 25,411 21,955 20,084 Current assets 66,619 60,786 62,451 Total assets 142, , ,662 Share capital 36,874 36,874 36,874 Reserves 43,233 43,562 41,141 Equity 80,107 80,436 78,015 Corporate Bonds 0 15,000 15,000 Financial lease liabilities 2,791 3,736 3,155 Non-current liabilities 2,791 18,736 18,155 Corporate Bonds 15, Financial lease liabilities 2,534 2,495 2,439 Trade payables 11,544 10,788 10,505 Short term bank loan 9,983 9,978 10,018 Other payables 10,674 6,852 10,394 Deferred revenue 9,454 8,313 8,136 Current liabilities 59,189 38,426 41,492 Total liabilities 61,980 57,162 59,647 Total equity and liabilities 142, , ,662 Page 7 of 9
8 CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED) Operating profit/(loss) (EBIT) 3, ,082 Depreciation and amortization 5,286 4,468 6,197 Non-cash adjustments (warrants) 829 2,879 3,854 Change in working capital 4,201-9,028-9,403 Profit on sale of assets Cash flows from primary activities 13,396-1,914-2,580 Net interest and value gains -3,251-2,006-3,497 Current tax 574 2,954 3,643 Cash flows from operating activities 10, ,434 Acquisition of intangible assets -3,044-1,998-2,382 Acquisition of property, plant and equipment ,324-2,595 Sale of assets Cash flows from investing activities -3,818-4,322-4,831 Repayment of lease debt -1,990-2,577-3,215 Repayment of deposit and loans Short term bank loan Cash flows from financing activities -2,047-2,669-2,859 Change in cash and cash equivalents 4,854-7,957-10,124 Unrealised currency gain/(loss) ,018 Cash and cash equivalents at the beginning of the period 20,084 29,190 29,190 Cash and cash equivalents at the end of the period 25,411 21,955 20,084 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED) Other reserves Number of shares Share capital Reserve for exchange adjustments Sharebased payment Retained profit Total Consolidated No. Equity at 1 January ,874,082 36, ,195 20,848 78,015 Profit/(loss) for the period Exchange adjustments relating to foreign subsidiaries Total comprehensive income ,263 Share-based payment Other transactions Equity at 30 September ,874,082 36, ,024 21,510 80,107 Equity at 1 January ,874,082 36, ,341 23,628 76,219 Profit/(loss) for the period Exchange adjustments relating to foreign subsidiaries Total comprehensive income ,338 Share-based payment 2,879 2,879 Other transactions , ,879 Equity at 30 September ,874,082 36, ,220 24,490 80,436 Page 8 of 9
9 NOTES TO THE INTERIM FINANCIAL STATEMENTS Note 1 Accounting policies The interim report of the Exiqon Group for the period 1 January 30 September 2015 is presented in accordance with IAS 34 and additional Danish disclosure requirements for the presentation of financial statements by listed companies. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group s Annual Report for The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in preparation of the Group s annual consolidated financial statements for the year that ended 31 December Management has not made new significant accounting estimates and assumptions on topics besides those listed in the Annual Report for Note 2 Revenue Product sales 27,940 22,594 85,018 70,904 96,269 Services 5,914 7,132 18,400 14,709 20,507 License income 2,302 3,623 6,618 7,292 8,912 Contract research and grants income 2,208 1,476 5,366 5,113 6,704 38,364 34, ,402 98, ,392 In the third quarter product sales includes OEM of DKK 2.4 million (DKK 2.9 million) and shipping and handling of DKK 0.8 million (DKK 0.6 million). Note 3 Segment information Exiqon s Management has organized the reporting in two reportable operating segments: Exiqon Life Sciences and Exiqon Diagnostics. The Group divides its revenue into three geographies: North America, Europe and Rest of World. The split is based on the registered offices of the customers. Management monitors the operating results of its business segments separately to decide the resource allocation and performance assessments. Segment performance is monitored on operating results (EBITDA/EBIT) as presented in the table below. Financial items and taxes are managed on a corporate level and not allocated to the operating segments. Life Sciences Diagnostics Group eliminations Other 1) Consolidated Revenue: External customers 113,015 2, ,402 Internal customers 27,844-27, Total revenue 140,859 2,387-27, ,402 EBITDA 20,615-12, ,366 Operating profit/(loss) (EBIT) 16,106-13, ,080 Net non-operating cost ,943-2,943 Profit (loss) before tax 16,106-13, , Assets 58,620 53, , ,087 1) The item Other includes net non-operating items. Geography Revenue of the Exiqon Group is distributed on geographical segments as follows: North America 15,597 12,052 45,257 33,683 45,576 Europe 18,750 19,583 56,922 53,404 72,000 Rest of World 4,017 3,190 13,223 10,931 14,816 38,364 34, ,402 98, ,392 --oo0oo-- Page 9 of 9
Exiqon A/S (NASDAQ OMX Copenhagen: EXQ ) today announced results for the first three months of 2015:
Interim report for the quarter 1 January 31 March 2015 Announcement No. 5/2015 To NASDAQ OMX Copenhagen A/S 7 May 2015 Exiqon A/S Skelstedet 16 2950 Vedbæk Denmark CVR nr. 18 98 44 31 Phone: +45 4566 0888
More informationContents. Part II Statements 28 Statement by Executive Board and Supervisory Board on the Annual Report 29 Independent Auditor's Reports
Annual Report 2015 Contents Part I Management Report 3 Exiqon 4 Five-Year Key Figures and Ratios 5 2015 Highlights 6 Exiqon Life Sciences 10 Exiqon Diagnostics 14 Risks 16 Financial Performance in 2015
More informationINTERIM REPORT FOR Q2 2017/18. (the period )
INTERIM REPORT FOR Q2 2017/18 (the period 01.01.2018-31.03.2018) ANNOUNCEMENT to Nasdaq Copenhagen A/S and the media Nørresundby, 1 May 2018 Announcement no. 9/2018 No. of pages: 12 GROWTH DESPITE UNFAVOURABLE
More informationINTERIM REPORT FOR Q3 2017/18. (the period )
INTERIM REPORT FOR Q3 2017/18 (the period 01.04.2018-30.06.2018) ANNOUNCEMENT to Nasdaq Copenhagen A/S and the media Nørresundby, 28 August 2018 Announcement no. 10/2018 No. of pages: 12 FULL YEAR GUIDANCE
More informationI. INTERIM MANAGEMENT REPORT... 2 II. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION... 5
2010 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT... 2 II. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION... 5 III. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE
More informationII. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS... 4
2018 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT... 2 II. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS... 4 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND
More informationInterim report for Q3 2014/15
announcement for NASDAQ OMX Copenhagen A/S and the press RTX Interim Report for the third quarter of 2014/15 1/15 Nørresundby, 24 August 2015 Financial Announcement no. 49/2015 No. of pages: 15 Interim
More informationVeloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017
Corporate Release Copenhagen, Denmark, 14 November 2017 INTERIM REPORT FOR THE PERIOD 1 JANUARY TO 30 SEPTEMBER 2017 Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017
More informationInterim Report. First half of 2017, BioPorto Group. August 10, 2017 Announcement no. 10. BioPorto A/S CVR DK
Interim Report First half of 2017, BioPorto Group August 10, 2017 Announcement no. 10 BioPorto A/S CVR DK-17500317 Highlights US Clinical study commencing according to announced plan BioPorto commenced
More informationII. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION... 5 VI. EXPLANATORY NOTES... 9
2014 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT... 2 II. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION... 5 III. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE
More informationINTERIM REPORT JUNE 1 ST, 2017 NOVEMBER 30 TH, 2017 (H1 2017/18)
To Nasdaq OMX Copenhagen A/S Company announcement no. 402 January 25 th, 2018 INTERIM REPORT JUNE 1 ST, 2017 NOVEMBER 30 TH, 2017 ( 2017/18) Main conclusions 2017/18 was approved at the Board of Director
More informationINTERIM REPORT FOR Q4 2014/15
ANNOUNCEMENT for NASDAQ OMX Copenhagen A/S and the press RTX INTERIM REPORT FOR THE FOURTH QUARTER OF 2014/15 1/15 Nørresundby, 25 November 2015 Financial Announcement no. 65/2015 No. of pages: 15 INTERIM
More informationInterim report for Q1 2014/15 (1 October - 31 December)
Interim report for 2014/15 (1 October - 31 December) continues to consolidate its global market position, posting revenue of DKK 388m and organic growth of 13% in Danish kroner, and 9% in local currencies.
More informationSix-month interim report (Q2) 2008 (unaudited)
To NASDAQ OMX Nordic Exchange Translation Company release No. 13/2008 Six-month interim report (Q2) 2008 (unaudited) Financial performance in the six months ended June 30, 2008 (Comparative figures for
More informationCOMPANY ANNOUNCEMENT. INTERIM REPORT OF HARBOES BRYGGERI A/S For the period 1 May 31 July 2011
COMPANY ANNOUNCEMENT Harboes Bryggeri A/S Tel. +45 58 16 88 88 Contacts: Bernhard Griese, CEO Ruth Schade, CFO INTERIM REPORT OF HARBOES BRYGGERI A/S For the period 1 May 31 July 2011 To NASDAQ OMX Copenhagen
More informationInterim report for Q3 2013/14 (1 April - 30 June)
Interim report for (1 April - 30 June) Organic growth in revenue of 8% and gross margin improved to 51.6%. EBIT increased by 41% to DKK 55m. The outlook for the year is maintained, and the estimated growth
More informationInterim report for Q2 2014/15 and for the period 1 October March 2015
Interim report for Q2 and for the period 1 October 2014-31 March 2015 increases revenue to DKK 483m. Organic growth of 9% was recorded in local currencies, and of 20% in Danish kroner. The outlook for
More informationInterim Financial Report for the Period 1 January 31 March 2014
Interim Financial Report for the Period 1 January 31 March 2014 Rørvang 3 * DK-2620 Albertslund * Denmark Tel: +45 70 28 00 00 * Fax: +45 70 28 01 01 * www.ao.dk CVR (Central Business Register) No.: 58
More informationVeloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
Corporate Release Copenhagen, Denmark, 14 May 2018 INTERIM REPORT FOR THE PERIOD 1 JANUARY TO 31 MARCH 2018 Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 Highlights
More informationCompany announcement from Vestas Wind Systems A/S
Company announcement from Randers, 22 November 2010 Page 1 of 33 New accounting policies for supply-and-installation projects and their effect on 2006-2011 Summary: In company announcement No. 40/2010
More informationInterim report for Q1 2015/16
Interim report for got off to a good start, posting revenue of DKK 462m and organic growth of 11% in local currencies, and 19% in Danish kroner. Earnings increased significantly to DKK 46m. is traditionally
More informationII. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION...
2017 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT...2 II. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS...4 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION...
More informationInterim report January September 2015
Boule Diagnostics AB (publ) Interim report January September 2015 Increased sales and a higher gross margin Quarter, July-September 2015 Net sales amounted to SEK 88.8 million (73.6), up 20.7 percent.
More informationViroGates releases third quarter 2018 results
Company announcement no. 7-2018 Birkerød, 24 October 2018 ViroGates releases third quarter 2018 results ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems for emergency departments
More informationZORLU ENERJİ ELEKTRİK ÜRETİM A.Ş. CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS AS OF 30 SEPTEMBER 2013 AND 31 DECEMBER 2012
CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS AS OF 30 SEPTEMBER 2013 AND 31 DECEMBER 2012 Audited ASSETS Note 30.09.2013 31.12.2012 Current Assets 471,526 594,414 Cash and Cash Equivalents 5 172,119 187,379
More informationNet interest-bearing debt at 30 September 2016 was DKK million (30 September 2015: DKK 476 million).
H+H International A/S Interim financial report Company Announcement No. 343, 2016 H+H International A/S Dampfærgevej 3, 3rd Floor 2100 Copenhagen Ø Denmark Tel. +45 35 27 02 00 info@hplush.com www.hplush.com
More informationINTERIM REPORT Q3 AND 9M 2014
INTERIM REPORT Q3 AND 9M 2014 THIRD QUARTER HIGHLIGHTS International market evaluation for Woulgan Biogel by Smith & Nephew continues at several sites in UK and Germany Woulgan Biogel survey ongoing in
More informationSix-month interim report (Q2) 2012 (unaudited)
To NASDAQ OMX Copenhagen A/S Six-month interim report (Q2) 2012 (unaudited) Company release No. 19/2012 Performance for the period (Comparative figures for the same period of last year are shown in brackets
More informationVeloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017
Corporate Release Copenhagen, Denmark, 16 May 2017 INTERIM REPORT FOR THE PERIOD 1 JANUARY TO 31 MARCH 2017 Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017 Highlights
More informationMolecular Diagnostic Solutions for Urologic Cancer
2018 All rights reserved 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 Full Year Financial Results February 22, 2018 2 Forward Looking Statement This presentation contains forward-looking statements
More informationInterim Financial Report for the Period 1 January 30 September 2013
Interim Financial Report for the Period 1 January 30 September 2013 Brødrene A & O Johansen A/S Rørvang 3 * DK-2620 Albertslund * Denmark Tel: +45 70 28 00 00 * Fax: +45 70 28 01 01 * www.ao.dk CVR (Central
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Healthcare Conference, September 2017 NASDAQ: NOVT 1 Safe Harbor Statement The statements in this presentation
More informationINTERIM REPORT Q INVESTOR CONFERENCE CALL. Company announcement no. 5/2017 August 29, 2017
Company announcement no. 5/2017 August 29, 2017 INTERIM REPORT Q2 2017 INVESTOR CONFERENCE CALL Welltec will discuss its results during an investor conference call today at 5pm CEST. The conference call
More informationAX V Nissens ApS. Ormhøjgårdvej 9, 8700 Horsens. CVR no
AX V Nissens ApS Ormhøjgårdvej 9, 8700 Horsens CVR no. 38 64 75 71 Interim financial report Third quarter 2018/19 1 November 2018-31 January 2019 Contents Statement by Management on the interim report
More informationINTERIM FINANCIAL REPORT First quarter 2018 Company announcement no. 690
INTERIM FINANCIAL REPORT First quarter 2018 Company announcement no. 690 1 May 2018 Selected financial and operating data for the period 1 January 31 March 2018 (DKKm) Q1 2018 Q1 2017 Net revenue 18,380
More informationInterpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
November 13, 2018 Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments Conference Call Tuesday, November 13, 2018 at 4:30 pm ET PARSIPPANY, NJ,,
More informationInterim Report. First Quarter 2018, BioPorto Group. May 3, 2018 Announcement no. 10. BioPorto A/S CVR DK
Interim Report First Quarter 2018, BioPorto Group May 3, 2018 Announcement no. 10 BioPorto A/S CVR DK-17500317 Highlights Important milestones in global rollout of The NGAL Test secured in first quarter
More informationContents Nilfisk Q2 Interim Report Q3 Interim Report 2017
Contents Nilfisk Q2 Interim Report 1 Interim Report Contents Nilfisk Q2 Interim Report 2 IN BRIEF Highlights of Performance in and the first nine months of in line with expectations The outlook for organic
More informationBoule Diagnostics AB (publ)
Boule Diagnostics AB (publ) Year-end report January December 2012 Continued strong sales growth Quarter October December 2012 Net sales totaled SEK 76.3 million (67.7), up 12.7 percent. Changes in the
More informationSix-month interim report (Q2) 2011 (unaudited)
To NASDAQ OMX Copenhagen A/S TRANSLATION Company release No. 14/2011 Six-month interim report (Q2) 2011 (unaudited) Performance for the period (Comparative figures for the same period of last year are
More informationQIAGEN reports results for third quarter and first nine months of 2018
QIAGEN reports results for third quarter and first nine months of 2018 Q3 2018 results exceed targets as QIAGEN on track to achieve 2018 goals: o sales of $377.9 million +3.8% reported (+6.5% at constant
More informationOperating profit margin was 9.3% in 6M 2018 in reported currencies compared to 9.6% in 6M 2017
Company announcement 8/218 August 17, 218 Financial report for the first six months of 218 NNIT delivers an operating profit margin of 9.3% and revenue growth of 2.9% in 6M 218 after a strong revenue growth
More informationSelling, general and administrative expenses 35,645 33,787. Net other operating income (292) (270) Operating profit 44,202 17,756
Condensed Interim Consolidated Income Statement For the quarter ended September 30 Continuing operations Revenue 328,071 258,941 Cost of sales 248,516 207,668 Gross profit 79,555 51,273 Selling, general
More informationInterim Report H1/2018
Interim Report H1/2018 Columbus A/S CVR.: 13 22 83 45 Columbus, Lautrupvang 6, DK-2750 Ballerup Phone: +45 70 20 50 00, Fax: +45 70 25 07 01 www.columbusglobal.com, CVR.: 13 22 83 45 2 Financial Statements
More informationINTERIM FINANCIAL REPORT H Company Announcement no. 704
INTERIM FINANCIAL REPORT H1 2018 Company Announcement no. 704 1 August 2018 Selected financial and operating data for the period 1 January - 30 June 2018 (DKKm) Q2 2018 Q2 2017 YTD 2018 YTD 2017 Net revenue
More informationMore precise outlook for 2012/13
Interim report for H1 2012/13 Copenhagen 5 February 2013 Rising gross margin and improved operating profit have been recorded for H1 2012/13. Management has decided to change brand portfolio, organisational
More informationMyriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results
May 8, 2018 Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results Total Revenues of $193.5 Million GAAP Diluted EPS of $0.16 and Adjusted EPS of $0.31 Up 15 Percent Company Raises Both Revenue
More information2008 REPORT. Agreement on the breast cancer test signed with SRL Ranbaxy. Indian multi-centre breast cancer study completed
Q2 28 REPORT 1ST HALF-YEAR HIGHLIGHTS: Agreement on the breast cancer test signed with SRL Ranbaxy Indian multi-centre breast cancer study completed NOK 44.8 million share issue European patent granted
More informationFinancials as expected after dividend pay-out
INTERIM REPORT Q2 2015 / Summary / 1 of 13 Company announcement no. 17/2015 August 18, 2015 Financials as expected after dividend pay-out In Q2 2015, DKK 8.5 billion was received in cash at closing of
More informationkey figures q , 2
key figures q1 2013 1, 2 unaudited; in millions of, except where otherwise stated orders continuing operations 19,141 19,792 Volume (5)% 3 Actual % Change Adjusted 3 Continuing operations Orders 19,141
More informationNNIT delivers an operating profit margin of 8.7% while revenue declines by 2.3% despite a revenue increase of 12% from non- Novo Nordisk customers
Company announcement 7/218 Søborg/Copenhagen, May 15, 218 Financial report for Q1 218 NNIT delivers an operating profit margin of 8.7% while revenue declines by 2.3% despite a revenue increase of 12% from
More informationIncreasing uncertainty and reduced profitability within core repair business
Interim Report 1 January - 30 June COMPANY ANNOUNCEMENT NO. 03/ 30 August Increasing uncertainty and reduced profitability within core repair business Mobylife has in Q2 experienced a continued negative
More informationFor personal use only
ASX RELEASE APPENDIX 4D & HALF-YEAR FINANCIAL REPORT 31 January 2018: Sienna Cancer Diagnostics (ASX:SDX), a medical technology company developing and commercialising innovative cancer-related tests for
More informationEBITDA before special items for the first quarter of 2017 was DKK 36.9 million (2016: DKK 36.6 million).
H+H International A/S Interim financial report Company Announcement No. 348 2017 H+H International A/S Dampfærgevej 3, 3rd Floor 2100 Copenhagen Ø Denmark Tel. +45 35 27 02 00 info@hplush.com www.hplush.com
More informationNet profit of DKK 151m in 9M 2018 compared to DKK 126m in 9M Free cash flow for 9M 2018 was DKK 116m compared to negative DKK 14m in 9M 2017
Company announcement 10/2018 October 25, 2018 Financial report for the first nine months of 2018 NNIT delivers revenue growth of 5.4% and an operating profit margin of 9.2% in 9M 2018 supporting the recent
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Industrial Conference, November 2017 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement
More informationCOMPANY ANNOUNCEMENT. Harboes Bryggeri A/S. Tel.: Ruth Schade, CFO
COMPANY ANNOUNCEMENT Tel.: +45 58 16 88 88 Contacts: Bernhard Griese, CEO Ruth Schade, CFO INTERIM REPORT OF HARBOES BRYGGERI A/S For the period 1 May - 31 July 2010 To NASDAQ OMX Copenhagen The Board
More informationQ3 Earnings Release/2003
This publication is available in Danish and English. In case of any discrepancies, the Danish version shall be the governing text. November 5, 2003 Announcement No. 18 Q3 Earnings Release/2003 At a meeting
More informationInterim report. January - September Interim report for the period January - September Third quarter July September 2014
Interim report January - September 2014 October 30, 2014 Interim report for the period January - September 2014 Third quarter July September 2014 Group net sales in the third quarter 2014 amounted to 118.5
More informationSummary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2018 February 6, 2018
Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2018 February 6, 2018 Listed company name : Sysmex Corporation Code : 6869 Listed stock
More informationINCREASED SALES AND SIGNIFICANTLY IMPROVED EARNINGS
INCREASED SALES AND SIGNIFICANTLY IMPROVED EARNINGS January September 2016 2015 Change (%) Net sales 13,030 9,770 +33 Expenses (31,325) (31,646) +1 EBITDA (11,503) (11,918) +3 EBITDA excluding legal fees
More informationBoule Diagnostics AB (publ)
Boule Diagnostics AB (publ) Year-end report January ember 2011 Continued positive growth in Asia Record delivery to India Quarter October ember 2011 * Net sales amounted to SEK 67.7 (67.0) million, corresponding
More informationInterim Financial Report for the Period 1 January 30 June 2016
Interim Financial Report for the Period 1 January 30 June 2016 Brødrene A & O Johansen A/S Rørvang 3 * DK-2620 Albertslund * Denmark Tel: +45 70 28 00 00 * Fax: +45 70 28 01 01 * www.ao.dk CVR (Central
More informationTruScreen Interim Report
2018 INTERIM REPORT TruScreen Interim Report 2018 1 CONTENTS Our Vision 03 Progress Against Strategic Goals 04 Half Year Results Snapshot 05 Chairman and CEO s Report 06 Interim Financial Statements 08
More informationINTERIM REPORT FOR THE PERIOD 1 JULY 2017 TO 30 SEPTEMBER 2017
IC GROUP Company Announcement no. 25 / INTERIM REPORT FOR THE PERIOD 1 JULY TO 30 SEPTEMBER Consolidated revenue for amounted to DKK 810 million (DKK 851 million) corresponding to a reduction of 4.8% or
More informationH Report. Medical Prognosis Institute A/S DECISION WITH PRECISION
H1 2016 Report Medical Prognosis Institute A/S DECISION WITH PRECISION August 31 st, 2016, Hoersholm, Denmark INTERIM REPORT FIRST HALF YEAR 2016 for the period January 1 st - June 30 th Highlights during
More informationInterim report, 1 January 30 September 2016
AroCell AB (publ) Interim report, 1 January 30 September 2016 Net sales were TSEK 46 (0) Loss after financial items was TSEK -6,637 (-5,857) Earnings per share where SEK -0.23 (-0.25) Cash flow from operating
More informationSolid performance continued with high sales growth and increased profitability
Report on the first nine months of 2018 for ROCKWOOL International A/S Release no. 11 2018 to Nasdaq Copenhagen 23 November 2018 Solid performance continued with high sales growth and increased profitability
More information6-Month Report January 1 June 30
6-Month Report 2010 January 1 June 30 02 GROUP KEY FIGURES EUR thousand (unless stated otherwise) Q2 2009 (unaudited) Q2 2010 (unaudited) H1 2009 (unaudited) H1 2010 (unaudited) Revenue 835 351 2,077 972
More informationMarket conditions are challenging causing unsatisfactory repair profitability and decreasing distribution activity
Interim Report 1 January - 30 September COMPANY ANNOUNCEMENT 23 November Market conditions are challenging causing unsatisfactory repair profitability and decreasing distribution activity Year to date,
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSimCorp reports revenue growth of 11% and EBIT margin of 21% for the first nine months of 2018
Company reg. no: 15 50 52 81 Company Announcement Company Announcement no. 12/2018 November 9, 2018 SimCorp reports revenue growth of 11% and EBIT margin of 21% for the first nine months of 2018 2018 highlights:
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers February 2018 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement The statements in this
More informationRosetta Genomics Reports Second Quarter 2010 Financial Results
Rosetta Genomics Reports Second Quarter 2010 Financial Results Test Volume Increases 170% Compared With the First Quarter Conference Call Scheduled for Wednesday, September 8 th at 10:00 a.m. Eastern Time
More informationÖSSUR Q3 RESULTS 2015
Announcement from Össur hf. No. 41/2015 Reykjavík, 22 October 2015 ÖSSUR Q3 RESULTS 2015 Highlights Q3 2015 Sales amounted to USD 117 million compared to USD 127 million in Q3 2014. Sales growth in local
More informationInterim report for the period 1 June - 31 August 2010 for Bang & Olufsen a/s
Interim report for the period 1 June - 31 August 2010 for Bang & Olufsen a/s As expected, the Group's turnover for the first quarter of the 2010/11 financial year was DKK 562 million against DKK 565 million
More informationHOLOGIC ANNOUNCES THIRD QUARTER FISCAL 2009 OPERATING RESULTS. Solid Quarterly Revenues and Performance
For Immediate Release Contact: Deborah R. Gordon Vice President, Investor Relations Hologic, Inc. (781) 999-7716 HOLOGIC ANNOUNCES THIRD QUARTER FISCAL 2009 OPERATING RESULTS Solid Quarterly Revenues and
More informationInvestor presentation June CEO Lars Marcher
Investor presentation June 2015 CEO Lars Marcher Agenda AMBU - transformation process Status on business Financials and outlook Q&A Disclaimer Forward-looking statements, especially such relating to future
More informationBoule Diagnostics AB (publ) Interim report January September Earnings more than doubled and continued sales success
Boule Diagnostics AB (publ) Interim report January September 2016 Earnings more than doubled and continued sales success Quarter July September 2016 Net sales amounted to SEK 108.5 million (88.8), up 22.2
More informationZealand Pharma A/S Interim report for the first nine months of 2013 (un-audited)
Company Announcement No. 25/2013 A/S Interim report for the first nine months of 2013 (un-audited) Net result of DKK -139 (EUR -19) million for the first nine months of 2013 Cash and securities of DKK
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 10-Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
More informationHaemonetics Reports 3 rd Quarter and Year-to-Date Fiscal 2019 Results; Raises Cash Flow Guidance and Reaffirms Other Fiscal 2019 Guidance
Earnings Release FY19 Q3 Investor Contacts Media Contact Gerry Gould, VP-Investor Relations Carla Burigatto, VP-Communications (781) 356-9402 (781) 348-7263 gerry.gould@haemonetics.com carla.burigatto@haemonetics.com
More informationINTERIM FINANCIAL REPORT Q Company Announcement no. 720
INTERIM FINANCIAL REPORT Q3 2018 Company Announcement no. 720 26 October 2018 Selected financial and operating data for the period 1 January - 30 September 2018 (DKKm) Q3 2018 Q3 2017 YTD 2018 YTD 2017
More informationQ Second Quarter 2016
Q2 2016 Second Quarter 2016 Highlights for the second quarter of 2016 o Group sales increased with NOK 3.8 million from NOK 11.5 million in the first quarter of 2016 to NOK 15.3 million in the second quarter
More informationQ3 Earnings Release/2004
This publication is available in Danish and English. In case of any discrepancies, the Danish version shall be the governing text. November 3, 2004 ANNOUNCEMENT NO: 29 Q3 Earnings Release/2004 At a meeting
More informationSummary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2019 February 6, 2019
Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2019 February 6, 2019 Listed company name : Sysmex Corporation Code : 6869 Listed stock
More informationConsolidated Statement of Financial Performance
Consolidated Statement of Financial Performance in CHF 1,000 Note 2018 2017 (reviewed) (reviewed) Revenue from product sales 3 1,822.7 909.5 Revenue from research & development 3 1,974.3 2,708.3 Other
More informationInterim report for the first half year 2016
Interim report for the first half year 2016 1 CONTENTS Report 3 Financial highlights and ratios 4 Management report 6 Outlook 6 Events after the end of the period 6 Stock Exchange announcements in 2016
More informationMolecular Diagnostics for Urologic Cancer. H Corporate Presentation
Molecular Diagnostics for Urologic Cancer H1 2018 Corporate Presentation FORWARD LOOKING STATEMENT This presentation contains forward-looking statements & estimates made by the management of the Company
More informationManagement Statement Management s Review Highlights Financial Review Interim Consolidated Income Statement...
CONTENTS Management Statement... 3 Management s Review...... 4 Highlights... 4 Financial Review... 5 Interim Consolidated Income Statement.... 8 Interim Consolidated Statement of Comprehensive Income...
More informationSix-month interim report (Q2) 2007: (unaudited)
To: The Copenhagen Stock Exchange Translation Announcement no. 14 2007 August 21, 2007 Six-month interim report (Q2) 2007: (unaudited) Financial performance in the six months ended June 30, 2007 (Comparative
More informationConsolidated financial statements 1 January - 31 March
Consolidated financial statements 1 January - Condensed income statement 1 January - Note Revenue 1.1, 1.2 1,694 1,885 Production costs (1,413) (1,508) Gross profit 281 377 Research and development costs
More informationAnnual Report. for. AroCell AB (publ)
Annual Report for AroCell AB (publ) 556596-6107 Fiscal Year 2016 1 (17) The Board of Directors and CEO of AroCell AB (publ), with its registered office in Uppsala, Sweden, hereby submit the annual report
More informationConsolidated financial statements 1 January - 31 March
Consolidated financial statements 1 January - Condensed income statement 1 January - Note Revenue 1.1 1,885 1,464 Production costs (1,508) (1,217) Gross profit 377 247 Research and development costs (42)
More informationH1INTERIM REPORT17. Company Announcement No. 8/30 August 2017 CONTENTS
SANTA FE RELO H1INTERIM REPORT17 Company Announcement No. 8/30 August 2017 CONTENTS MANAGEMENT REVIEW HIGHLIGHTS H1 02 FINANCIAL HIGHLIGHTS AND KEY RATIOS 03 FINANCIAL REVIEW 04 BUSINESS LINE PERFORMANCE
More informationRIAS A/S HALF-YEAR REPORT
Page 1 of 17 NASDAQ OMX Copenhagen A/S PO Box 1040 DK-1007 Copenhagen K Roskilde, 17 May 2017 RIAS A/S HALF-YEAR REPORT FOR THE PERIOD 1 October 2016 31 March 2017 CVR 44 06 51 18 Company Announcement
More informationContents Nilfisk Q2 Interim Report Q2 Interim Report 2017
Nilfisk Interim Report 1 Interim Report Nilfisk Interim Report 2 IN BRIEF Highlights of Performance in and the first half of in line with expectations 1.7% organic revenue growth for Nilfisk in and 3.0%
More informationNeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013
July 31, 2013 NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013 FT. MYERS, Fla., July 31, 2013 /PRNewswire/ -- NeoGenomics,
More informationInterim report January March 2009
Interim report January March 2009 Vitrolife AB (publ) Strong conclusion to a record quarter Sales increased by 22 percent to SEK 71.8 (58.7) million. Calculated in local currencies growth was 4 percent.
More informationInterim report Q1 2016/17 (1 April 30 June 2016)
Company announcement no. 14 2016/17 Allerød, 16 August 2016 Interim report Q1 2016/17 (1 April 30 June 2016) Growing revenue guidance confirmed new share buyback programme Q1 2016/17 revenue was up by
More information